Trial · NCT04818346
Adverse events92
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 92
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acne | Skin and subcutaneous tissue disorders | Placebo | 0 | 42 | 0 |
| other | Acne | Skin and subcutaneous tissue disorders | Povorcitinib 15 mg | 0 | 43 | 0 |
| other | Acne | Skin and subcutaneous tissue disorders | Povorcitinib 45 mg | 3 | 41 | 3 |
| other | Acne | Skin and subcutaneous tissue disorders | Povorcitinib 75 mg | 22 | 114 | 28 |
| other | Alanine aminotransferase increased | Investigations | Placebo | 1 | 42 | 1 |
| other | Alanine aminotransferase increased | Investigations | Povorcitinib 15 mg | 1 | 43 | 1 |
| other | Alanine aminotransferase increased | Investigations | Povorcitinib 45 mg | 3 | 41 | 3 |
| other | Alanine aminotransferase increased | Investigations | Povorcitinib 75 mg | 6 | 114 | 6 |
| other | Aspartate aminotransferase increased | Investigations | Placebo | 1 | 42 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Povorcitinib 15 mg | 1 | 43 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Povorcitinib 45 mg | 4 | 41 | 5 |
| other | Aspartate aminotransferase increased | Investigations | Povorcitinib 75 mg | 4 | 114 | 4 |
| other | Blood creatine phosphokinase increased | Investigations | Placebo | 3 | 42 | 3 |
| other | Blood creatine phosphokinase increased | Investigations | Povorcitinib 15 mg | 3 | 43 | 3 |
| other | Blood creatine phosphokinase increased | Investigations | Povorcitinib 45 mg | 4 | 41 | 6 |
| other | Blood creatine phosphokinase increased | Investigations | Povorcitinib 75 mg | 21 | 114 | 25 |
| other | COVID-19 | Infections and infestations | Placebo | 5 | 42 | 5 |
| other | COVID-19 | Infections and infestations | Povorcitinib 15 mg | 8 | 43 | 8 |
| other | COVID-19 | Infections and infestations | Povorcitinib 45 mg | 13 | 41 | 14 |
| other | COVID-19 | Infections and infestations | Povorcitinib 75 mg | 31 | 114 | 31 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04818346/events